Table 4 Hazard ratio for all-cause mortality associated with the presence of cancer in patients with intact AAA
All-cause mortality | Crude HR (95% CIs) | Adjusted HR (95% CIs)* | ||||
|---|---|---|---|---|---|---|
Model 1 | Model 2 | |||||
Patients with intact AAA treated by EVAR or OSR (n = 11,785) | ||||||
30-day mortality | 0.85 | (0.52–1.38) | 0.83 | (0.50–1.36) | 0.80 | (0.49–1.31) |
90-day mortality | 1.30 | (0.99–1.69) | 1.20 | (0.92–1.58) | 1.16 | (0.89–1.53) |
Total mortality | 1.50 | (1.35–1.67) | 1.31 | (1.18–1.46) | 1.31 | (1.17–1.46) |
Patients with intact AAA treated by EVAR (n = 7903) | ||||||
30-day mortality | 0.80 | (0.45–1.43) | 0.82 | (0.46–1.46) | 0.80 | (0.45–1.43) |
90-day mortality | 1.19 | (0.88–1.62) | 1.17 | (0.86–1.60) | 1.14 | (0.83–1.55) |
Total mortality | 1.40 | (1.24–1.58) | 1.29 | (1.14–1.46) | 1.28 | (1.13–1.46) |
Patients with intact AAA treated by OSR (n = 3882) | ||||||
30-day mortality | 1.02 | (0.40–2.58) | 0.96 | (0.37–2.45) | 0.87 | (0.34–2.24) |
90-day mortality | 1.57 | (0.90–2.73) | 1.35 | (0.77–2.36) | 1.28 | (0.73–2.24) |
Total mortality | 1.55 | (1.24–1.94) | 1.32 | (1.06–1.65) | 1.33 | (1.06–1.66) |